$0.82
-0.05 (-5.90%)
Open$0.88
Previous Close$0.87
Day High$0.88
Day Low$0.81
52W High$2.73
52W Low$0.80
Volume—
Avg Volume44.9K
Market Cap9.13M
P/E Ratio—
EPS$-2.05
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+4,847.0% upside
Current
$0.82
$0.82
Target
$40.58
$40.58
$25.27
$40.58 avg
$56.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.34M | 7.69M | 6.20M |
| Net Income | 836.8K | 704.4K | 655.3K |
| Profit Margin | 11.4% | 9.2% | 10.6% |
| EBITDA | 1.33M | 1.40M | 1.15M |
| Free Cash Flow | 524.0K | 541.1K | 340.9K |
| Rev Growth | +8.2% | -3.9% | -5.2% |
| Debt/Equity | 0.19 | 0.19 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |